Clinical Results from COVID Vaccine Patent Agreement: A Month of News Including CEO Stock Sales

Roivant Sciences Ltd. (NASDAQ: ROIV) announced that its subsidiaries Genevant and Arbutus have finalized a global settlement with Moderna to resolve their COVID-19 vaccine intellectual property dispute for up to $2.25 billion (approximately KRW 3 trillion). Of that amount, $950 million (about KRW 1.2 trillion) will be paid in a lump sum by July 8, and the remaining up to $1.3 billion (roughly KRW 1.7 trillion) will be determined based on the outcome of litigation related to U.S. government supply volumes.

On April 2, Roivant affiliate Priovant initiated a Phase 2b/3 clinical trial of brepocitinib for lichen planopilaris (LPP), an inflammatory condition that causes hair loss. At the same time, another affiliate, Immunovant, has begun reevaluating its development strategy after two Phase 3 studies of its thyroid eye disease (TED) candidate batoclimab failed to meet the primary endpoint of proptosis improvement.

According to an April 16 SEC filing, CEO Matthew Gline sold approximately 290,000 shares of common stock on the open market at $29.16 per share, realizing about $8.45 million (roughly KRW 11 billion). He continues to hold over 16.7 million shares following the transaction.

In its Q4 2025 earnings report released in early February, Roivant said revenue remained modest and it posted another loss driven by higher research-and-development and stock-based compensation expenses. More recently, buoyed by the Moderna settlement and optimism around its rare disease pipeline, the company’s shares reached an all-time high near $27 on the Nasdaq. Major brokerages including Goldman Sachs have maintained overweight ratings and raised their price targets to $38.

Roivant is a U.S.-based biotech platform company that develops novel therapies in immunology and rare diseases through a network of affiliated “vants,” both public and private—including Immunovant, Priovant and Genevant. As the platform model—separating assets to enable flexible development and partnerships—gains traction in the U.S. biotech sector, Roivant is strengthening its presence with an mRNA/LNP patent portfolio and an autoimmunity antibody pipeline.